PI16 attenuates response to sorafenib and represents a predictive biomarker in hepatocellular carcinoma

Sorafenib has become the only FDA‐approved first‐line therapy for advanced hepatocellular carcinoma (HCC) for more than 10 years, but there is still no validated predictive or prognostic marker. Peptidase inhibitor 16 (PI16) is a functionally unknown gene in cancer research. This study aimed to dete...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Pusen, Jiang, Zhongyi, Liu, Xueni, Yu, Kanru, Wang, Chunguang, Li, Hao, Zhong, Lin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7541153/
https://www.ncbi.nlm.nih.gov/pubmed/32779397
http://dx.doi.org/10.1002/cam4.3331

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7541153/
https://www.ncbi.nlm.nih.gov/pubmed/32779397
http://dx.doi.org/10.1002/cam4.3331

Ejemplares similares